PubRank

Jonathan S Berek

Author PubWeight™ 58.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 2009 5.59
2 Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011 5.28
3 Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005 4.27
4 Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol 2013 3.08
5 Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2009 2.32
6 Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 2007 1.82
7 Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008 1.74
8 U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women? Obstet Gynecol 2016 1.70
9 Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006 1.52
10 Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007 1.49
11 Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol 2005 1.31
12 Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol 2007 1.18
13 Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. Gynecol Oncol 2006 1.16
14 FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. Nat Commun 2012 1.12
15 Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer 2007 1.11
16 Elective oophorectomy for benign gynecological disorders. Menopause 2007 1.11
17 CA125: megadaltons of novel opportunities. Gynecol Oncol 2007 1.07
18 Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol 2007 0.99
19 The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol 2009 0.99
20 A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 2011 0.97
21 Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 2003 0.94
22 Ovarian conservation at the time of hysterectomy for benign disease. Clin Obstet Gynecol 2007 0.93
23 The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. Gynecol Oncol 2006 0.90
24 Personalizing CA125 levels for ovarian cancer screening. Cancer Prev Res (Phila) 2011 0.90
25 Lymphovascular and perineural invasion in the parametria: a prognostic factor for early-stage cervical cancer. Obstet Gynecol 2003 0.89
26 Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol 2013 0.89
27 Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. Am J Obstet Gynecol 2008 0.89
28 Surgery for ovarian cancer: how to improve survival. Lancet 2006 0.89
29 Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol 2014 0.89
30 Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res 2013 0.87
31 TLR3 agonists as immunotherapeutic agents. Immunotherapy 2010 0.87
32 HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. Gynecol Oncol 2008 0.86
33 Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol 2007 0.85
34 Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol 2007 0.84
35 Intraperitoneal chemotherapy for ovarian cancer. Curr Opin Oncol 2006 0.84
36 Current management of vulvar cancer. Hematol Oncol Clin North Am 2012 0.83
37 Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2005 0.82
38 Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol 2010 0.81
39 Elective oophorectomy in the gynecological patient: when is it desirable? Curr Opin Obstet Gynecol 2007 0.81
40 Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther 2005 0.77
41 Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2003 0.77
42 Salpingo-Oophorectomy at the Time of Benign Hysterectomy: A Systematic Review. Obstet Gynecol 2017 0.77
43 In reply. Obstet Gynecol 2013 0.75
44 Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience. Int J Gynecol Cancer 2009 0.75
45 In Reply. Obstet Gynecol 2016 0.75
46 Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecol Oncol 2003 0.75
47 Lower urinary tract reconstruction with ileum in the treatment of gynecologic malignancies. Gynecol Oncol 2005 0.75
48 Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Clin Cancer Res 2004 0.75
49 Cervical cancer: an opportunity to prevent and cure. Cancer J 2003 0.75